Jaguar Health sets October 16 ex-date for dividend on Jaguar Health stock

Published on 10/16/2026 at 02:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The Series R dividend pays October 15, 2026, and each share converts into five common shares. The October 16 ex-date applies to Jaguar Health stock.

Dividend mechanics and key dates

Jaguar Health confirmed the October 16, 2026 ex-dividend date for its Series R distribution.
Each preferred share converts into five common shares on November 2, 2026.
Jaguar Health had a USD 8.9 million market capitalization as of October 15, 2026.

JAGX, US47010C8543, Illustration mit AI erstellt.

Jaguar Health (US47010C8543) has an October 16, 2026 ex-dividend date for its Series R Convertible Preferred Stock, according to Morningstar on October 14, 2026. The distribution is payable October 15, while each preferred share is scheduled to convert into five common shares on November 2, 2026.

What does the dividend change?

The structure gives eligible holders one Series R preferred share for each common share held on the October 13 record date. The preferred security carries a five-for-one conversion feature, creating a clearly defined share-count event for investors tracking Jaguar's capital structure.

Jaguar's October 14 update said Nasdaq would use due bills through the October 16 ex-dividend date. Those due bills transfer the right to receive the dividend between buyers and sellers during the dividend-right period, according to Morningstar.

Three dated steps for JAGX

On October 2, 2026, Jaguar announced the special dividend, setting the October 13 record date and the November 2 conversion date, according to the Jaguar Health release. On October 6, its Napo Pharmaceuticals unit announced an intestinal-failure panel for October 30. On October 14, preliminary crofelemer study data were presented from four participants who completed the treatment protocol, as reported by GuruFocus.

What comes next for holders?

The next dated company-related events are the October 30, 2026 intestinal-failure panel and the November 2, 2026 conversion of each Series R preferred share into five common shares. Jaguar has also described a planned mid-2027 New Drug Application filing for crofelemer in microvillus inclusion disease.

Small-cap valuation remains central

Jaguar Health had a USD 8.9 million market capitalization as of October 15, 2026. Its business centers on plant-derived prescription medicines, including crofelemer for gastrointestinal disorders and the Napo Pharmaceuticals development program.